A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult Participants

Sponsor
Pfizer
Study ID
NCT06675188
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • PF-07275315 — DRUG
    PF-07275315 solution for injection (single use only)
  • Placebo — OTHER
    Placebo solution for injection (single use only)

Study Details

The purpose of this study is to learn if the study medicine (called PF-07275315) is safe and how it is processed in healthy Chinese participants. This study is seeking participants who: * Are between 18 to 65 years of age. * Are Chinese participants who are overtly healthy as determined by medical evaluation. * Have a BMI (body mass index) of 19 to 28 kilogram per meter squared; and a total body weight of more than50 kilograms (110 pounds). All participants in this study will receive study medicine. About three-fourths will receive PF-07275315 and one-fourth will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The study medicine will be given as an IV infusion (directly into a vein) at the study clinic only one time. The study will compare the experiences of people receiving PF-07275315 to those of people who do not. This will help see if PF-07275315 is safe and how it behaves inside the human body. Participants will take part in this study for up to 181 days. During this time, the participants will stay at the study clinic for 5 days. After the stay, the participants will have 8 study visits at the study clinic.

Key Dates

Start date
Jan 6, 2025
Status verified
Aug 2025
Primary completion
Jul 14, 2025
Completion
Jul 14, 2025

Study Design

Enrollment
13 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: PF-07275315
    Participants will receive a single dose of PF-07275315 via IV infusion
  • Placebo Comparator: Placebo
    Participants will receive a single dose of placebo via IV infusion

Primary Outcome Measure

Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Up to Day 181 ]

Related Studies